PreprintArticleVersion 1This version is not peer-reviewed
B- and T-cell Specific Responses to Vaccination against SARS-CoV-2 in Anti-CD20 Treated Patients with Relapsing-Remitting or Progressive Form of Multiple Sclerosis Reveal Immunosenescent Features
Version 1
: Received: 3 July 2024 / Approved: 4 July 2024 / Online: 4 July 2024 (10:51:20 CEST)
How to cite:
De Biasi, S.; Ciobanu, A. L.; Santacroce, E.; Lo Tartaro, D.; Degliesposti, G.; D'Angerio, M.; Leccese, M.; Cardi, M.; Trenti, T.; Cuccorese, M.; Gibellini, L.; Ferraro, D.; Cossarizza, A. B- and T-cell Specific Responses to Vaccination against SARS-CoV-2 in Anti-CD20 Treated Patients with Relapsing-Remitting or Progressive Form of Multiple Sclerosis Reveal Immunosenescent Features. Preprints2024, 2024070381. https://doi.org/10.20944/preprints202407.0381.v1
De Biasi, S.; Ciobanu, A. L.; Santacroce, E.; Lo Tartaro, D.; Degliesposti, G.; D'Angerio, M.; Leccese, M.; Cardi, M.; Trenti, T.; Cuccorese, M.; Gibellini, L.; Ferraro, D.; Cossarizza, A. B- and T-cell Specific Responses to Vaccination against SARS-CoV-2 in Anti-CD20 Treated Patients with Relapsing-Remitting or Progressive Form of Multiple Sclerosis Reveal Immunosenescent Features. Preprints 2024, 2024070381. https://doi.org/10.20944/preprints202407.0381.v1
De Biasi, S.; Ciobanu, A. L.; Santacroce, E.; Lo Tartaro, D.; Degliesposti, G.; D'Angerio, M.; Leccese, M.; Cardi, M.; Trenti, T.; Cuccorese, M.; Gibellini, L.; Ferraro, D.; Cossarizza, A. B- and T-cell Specific Responses to Vaccination against SARS-CoV-2 in Anti-CD20 Treated Patients with Relapsing-Remitting or Progressive Form of Multiple Sclerosis Reveal Immunosenescent Features. Preprints2024, 2024070381. https://doi.org/10.20944/preprints202407.0381.v1
APA Style
De Biasi, S., Ciobanu, A. L., Santacroce, E., Lo Tartaro, D., Degliesposti, G., D'Angerio, M., Leccese, M., Cardi, M., Trenti, T., Cuccorese, M., Gibellini, L., Ferraro, D., & Cossarizza, A. (2024). B- and T-cell Specific Responses to Vaccination against SARS-CoV-2 in Anti-CD20 Treated Patients with Relapsing-Remitting or Progressive Form of Multiple Sclerosis Reveal Immunosenescent Features. Preprints. https://doi.org/10.20944/preprints202407.0381.v1
Chicago/Turabian Style
De Biasi, S., Diana Ferraro and Andrea Cossarizza. 2024 "B- and T-cell Specific Responses to Vaccination against SARS-CoV-2 in Anti-CD20 Treated Patients with Relapsing-Remitting or Progressive Form of Multiple Sclerosis Reveal Immunosenescent Features" Preprints. https://doi.org/10.20944/preprints202407.0381.v1
Abstract
Clinical, pathological, and imaging evidence in multiple sclerosis (MS) shows that inflammation starts early and progresses with age. B cells play a central role in this process, contributing to cytokine production, defective regulatory functions, and abnormal immunoglobulin production, even in the central nervous system. Anti-CD20 (aCD20) therapies, which deplete CD20+ B cells, are effective for both relapsing-remitting (RR) and progressive-relapsing (PR) MS. While effective against MS symptoms and lesions detectable by magnetic resonance imaging, aCD20 therapies can reduce the immune response to COVID-19 vaccination. By using high-parameter flow cytometry, we examined the antigen-specific (Ag+) immune response six months post-third COVID-19 mRNA-vaccination in MS patients with RR and PR forms on aCD20 therapy. Despite lower Ag+ B cell responses and lower levels of anti-SARS-CoV2, both total and neutralizing antibodies, RR and PR patients developed strong Ag+ T cell responses. We observed similar percentages and numbers of Ag+ CD4+ T cells and high proportion of Ag+ CD8+ T cells, with slight differences in T cell phenotype and functionality, that however suggested the presence of differences in immune responses driven by age and disease severity.
Biology and Life Sciences, Immunology and Microbiology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
